| Phase 13 trials |
|
Phase 1
|
NCT06843460 |
Nov 2023 → May 2024 |
— |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01562405 |
May 2012 → Dec 2026 expected |
plasma cell myeloma |
Massachusetts General Hospital |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT00709540 |
Jan → Nov 2008 |
osteoporosis |
Acceleron Pharma, Inc. |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT01464164 |
Jan 2012 → Apr 2021 |
Diamond-Blackfan anemia |
Northwell Health |
Terminated
|
No outcome recorded
|
| Phase 220 trials |
|
Phase 2
|
NCT07498803 |
Sep 2026 → Mar 2028 expected |
Eisenmenger syndrome, congenital heart disease |
Philipps University Marburg |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07646860 |
Aug 2026 → May 2029 expected |
pulmonary arterial hypertension |
Merck Sharp & Dohme LLC |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07266519 |
Jul 2026 → Oct 2028 expected |
pulmonary arterial hypertension |
Philipps University Marburg |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06925750 |
May 2025 → Jun 2028 expected |
pulmonary arterial hypertension |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06814145 |
Apr 2025 → Aug 2035 expected |
pulmonary hypertension |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06664801 |
Nov 2024 → Nov 2025 |
pulmonary arterial hypertension |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05587712 |
Jan 2023 → Sep 2028 expected |
pulmonary arterial hypertension |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04945460 |
Dec 2021 → Sep 2025 |
pulmonary hypertension |
Acceleron Pharma, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03738150 |
Apr 2019 → Dec 2021 |
pulmonary arterial hypertension |
Acceleron Pharma, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03496207 |
Jun 2018 → Mar 2022 |
pulmonary arterial hypertension |
Acceleron Pharma, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02230917 |
Oct 2014 → Apr 2016 |
plasma cell myeloma |
Rebecca Silbermann |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT01999582 |
Nov 2013 → Aug 2016 |
anemia, chronic renal failure syndrome |
Celgene Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01712308 |
Feb 2013 → May 2022 |
anemia, myelodysplastic/myeloproliferative neoplasm, myelofibrosis |
M.D. Anderson Cancer Center |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01736683 |
Nov 2012 → Apr 2018 |
anemia, chronic myelomonocytic leukemia, myelodysplastic syndrome |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01571635 |
Oct 2012 → Jul 2015 |
beta-thalassemia intermedia, beta-thalassemia major |
Celgene Corporation |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT01284348 |
Mar 2011 → Sep 2012 |
anemia, cervical cancer, head and neck cancer, non-small cell lung carcinoma +2 |
Merck Sharp & Dohme LLC |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT01146574 |
Jun 2010 → Mar 2016 |
anemia |
Celgene Corporation |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01190644 |
Jun 2010 → Sep 2012 |
cancer |
Merck Sharp & Dohme LLC |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT00931606 |
Jun 2009 → Nov 2010 |
aregenerative anemia |
Merck Sharp & Dohme LLC |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT00747123 |
Sep 2008 → Aug 2009 |
plasma cell myeloma |
Celgene Corporation |
Completed
|
No outcome recorded
|
|
| Phase 35 trials |
|
Phase 3
|
NCT05818137 |
May 2023 → Mar 2024 |
pulmonary arterial hypertension |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04811092 |
Mar 2022 → Apr 2025 |
pulmonary arterial hypertension |
Acceleron Pharma, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 3
|
NCT04896008 |
Dec 2021 → Jul 2024 |
pulmonary arterial hypertension |
Acceleron Pharma, Inc. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT07218029 |
May 2021 → Dec 2028 expected |
pulmonary arterial hypertension |
Merck Sharp & Dohme LLC |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT04576988 |
Jan 2021 → Aug 2022 |
pulmonary arterial hypertension |
Acceleron Pharma, Inc. |
Completed
|
No outcome recorded
|
| Phase 45 trials |
|
Phase 4
|
NCT07600723 |
Jul 2026 → Apr 2028 expected |
pulmonary arterial hypertension |
Merck Sharp & Dohme LLC |
Not yet recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT07356778 |
Oct 2025 → Aug 2027 expected |
Eisenmenger syndrome |
Kazuya Hosokawa |
Recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT07140484 |
Oct 2025 → Jan 2029 expected |
pulmonary arterial hypertension |
University of Alberta |
Recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT06658522 |
May 2025 → May 2026 overdue |
pulmonary arterial hypertension |
Amsterdam UMC, location VUmc |
Recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT06409026 |
Jul 2024 → Jan 2026 |
pulmonary arterial hypertension |
Mayo Clinic |
Completed
|
No outcome recorded
|